Unknown

Dataset Information

Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review.


ABSTRACT: Lung cancer ranks first as the cause of cancer-associated deaths gobally. The American Cancer Society estimates for 228,820 new cases and 135,720 deaths from lung cancer in the United States for the year 2020. Targeted treatment options have rapidly emerged for non-small cell lung cancer (NSCLC) within the past decade. Screening for molecular aberrations is mainly done by tissue biopsy. However, in some cases a biopsy is not possible, or patients do not consent to it. Hence, liquid biopsy remains the only option. Relevant data about the topic of liquid biopsy, with a special focus on NSCLC, was obtained via a PubMed search. We included mainly literature published from 2010 onwards, omitting older studies whenever possible. With this review of the literature, we give an overview of differen

SUBMITTER: Smolle E 

PROVIDER: S-EPMC8182706 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature